SPARSENTAN

Information current as at: 1 July 2026

PBAC meeting date: November 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Filspari®
Form and strength:
  • Tablet 200 mg
  • Tablet 400 mg
Submission sponsor:
SEQIRUS (AUSTRALIA) PTY LTD
Condition/indication:
(therapeutic use)
  • Immunoglobulin A nephropathy (IgAN)
Listing requested:
To request listing of sparsentan for the treatment of adult patients with IgAN who have persistent proteinuria (that is, a urine protein excretion ≥ 1.0 g/day) despite at least 12 weeks of stable optimised therapy with an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB).
Funding program:
PBS General Schedule
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2026 PBAC meeting
2Opportunity for consumer comment:
Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
4PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a1309
Page last updated
23 July 2026
Return to the Medicine Status Listing
v.9.19